Respiratory infections in humans can be caused by different etiological agents, such as viruses and bacteria. The high mutation rate of viruses, the appearance of resistance to current treatments, as well as the emergence of new strains, make it imperative to have technology that allows the analysis of a battery of etiological agents in a single analysis, maximizing the amount of information at a low cost.
This type of complete analysis provides an improvement to the health system even after the end of the pandemic, because it gives the physician the possibility of having a diagnosis of certainty of the etiological agent that is causing the acute respiratory infection, which allows him to implement the most appropriate therapy, know the prognosis and evolution of the infection, separate hospitalized patients with different viruses or bacteria, control the spread of intrahospital pathogens, identify resistance to antivirals, and also to conduct epidemiological studies on the agents that affect the population.
The Respiratory Panel KIT is based on IRIS technology and allows to analyze at the same time and in a single analysis 15 viruses (Adenovirus; Parainfluenza 1, 2, 3 and 4; Rhinovirus/Enterovirus; RSV; Coronavirus 229E; Coronavirus HKU1; Coronavirus NL63; Coronavirus OC43; Coronavirus SARS-CoV-2; Generic Influenza A; Influenza A H3N2; Influenza A H1N1 (2009) and Generic Influenza B) and 3 Bacteria (Mycoplasma pneumoniae, Chlamydia pneumoniae and Bordetella pertussis).
This kit is developed and validated in its "Research Use Only" (RUO) format, it is not approved as an IVD kit by ANMAT (regulatory body in Argentina as FDA in the USA).